TW202045516A - 雙環磺醯胺 - Google Patents

雙環磺醯胺 Download PDF

Info

Publication number
TW202045516A
TW202045516A TW109104831A TW109104831A TW202045516A TW 202045516 A TW202045516 A TW 202045516A TW 109104831 A TW109104831 A TW 109104831A TW 109104831 A TW109104831 A TW 109104831A TW 202045516 A TW202045516 A TW 202045516A
Authority
TW
Taiwan
Prior art keywords
substituted
compound
pharmaceutically acceptable
acceptable salt
group
Prior art date
Application number
TW109104831A
Other languages
English (en)
Chinese (zh)
Inventor
里歐尼德 畢戈曼
大衛 伯納德 史密斯
Original Assignee
美商艾利格斯醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾利格斯醫療公司 filed Critical 美商艾利格斯醫療公司
Publication of TW202045516A publication Critical patent/TW202045516A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109104831A 2019-02-14 2020-02-14 雙環磺醯胺 TW202045516A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962805725P 2019-02-14 2019-02-14
US62/805,725 2019-02-14

Publications (1)

Publication Number Publication Date
TW202045516A true TW202045516A (zh) 2020-12-16

Family

ID=72045615

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109104831A TW202045516A (zh) 2019-02-14 2020-02-14 雙環磺醯胺

Country Status (13)

Country Link
US (1) US11033556B2 (cg-RX-API-DMAC7.html)
EP (1) EP3924357A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022519764A (cg-RX-API-DMAC7.html)
KR (1) KR20210126636A (cg-RX-API-DMAC7.html)
CN (1) CN113423712A (cg-RX-API-DMAC7.html)
AU (1) AU2020221839B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015864A2 (cg-RX-API-DMAC7.html)
CA (1) CA3128061A1 (cg-RX-API-DMAC7.html)
IL (1) IL284940A (cg-RX-API-DMAC7.html)
MX (1) MX2021009717A (cg-RX-API-DMAC7.html)
SG (1) SG11202108835SA (cg-RX-API-DMAC7.html)
TW (1) TW202045516A (cg-RX-API-DMAC7.html)
WO (1) WO2020167984A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220024192A (ko) 2019-05-31 2022-03-03 알리고스 테라퓨틱스 인코포레이티드 변형된 갭머 올리고뉴클레오타이드 및 사용 방법
CN115160344A (zh) * 2021-04-06 2022-10-11 上海长森药业有限公司 通过口服给药抑制CD4+Treg细胞的药物和方法
KR20240099159A (ko) 2021-09-08 2024-06-28 알리고스 테라퓨틱스 인코포레이티드 변형된 짧은 간섭 핵산(sina) 분자 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10875876B2 (en) * 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108264520B (zh) * 2017-01-03 2021-12-07 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
CN109251212A (zh) * 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Also Published As

Publication number Publication date
JP2022519764A (ja) 2022-03-24
AU2020221839B2 (en) 2024-09-12
SG11202108835SA (en) 2021-09-29
KR20210126636A (ko) 2021-10-20
EP3924357A4 (en) 2023-02-22
WO2020167984A1 (en) 2020-08-20
CN113423712A (zh) 2021-09-21
MX2021009717A (es) 2021-09-14
US20200345749A1 (en) 2020-11-05
AU2020221839A1 (en) 2021-08-19
BR112021015864A2 (pt) 2021-10-05
IL284940A (en) 2021-09-30
US11033556B2 (en) 2021-06-15
CA3128061A1 (en) 2020-08-20
EP3924357A1 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
JP6553551B2 (ja) B型肝炎抗ウイルス剤
TWI721016B (zh) B型肝炎核心蛋白質調節劑
TW201927789A (zh) B型肝炎抗病毒試劑
TWI819213B (zh) 雙環及三環化合物
TWI846853B (zh) 吡咯化合物
TW201639850A (zh) 氮雜吡啶酮化合物及其用途
US11136321B2 (en) Tricyclic compounds
US11033556B2 (en) Bicyclic sulfonamides
JP2021503466A (ja) 抗HBVのテトラヒドロイソキサゾロ[4,3−c]ピリジン類化合物
CA3178647A1 (en) Substituted tricyclic amides, analogues thereof, and methods using same
JP2023519870A (ja) インフルエンザウイルスエンドヌクレアーゼの三環式阻害剤
US20220000874A1 (en) Tricyclic compounds
US20240368096A1 (en) Fused Heterobicyclic Antiviral Agents
EP4161916A1 (en) Substituted isoquinolinylmethyl amides, analogues thereof, and methods using same
NZ625614B2 (en) Hepatitis b antiviral agents